On August 8, 2020 MonTa Biosciences reported that have completed our regulatory meeting with the Danish Medicines Agency to align views on development strategy and interpretation of ICH guidelines (Press release, MonTa Biosciences, AUG 8, 2020, View Source [SID1234618678]). MonTas plan for moving our lead candidate MBS8 into the clinic was well supported, securing a clear path forward toward, and a smooth process for our Clinical Trial Application filed in the near future. Thanks to our consultants Ozack and Ingrid Bøgh for great help in the process.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!